Effects of MDM2is in human lymphoma cell lines in vitro. (A-B) Dose response to MDM2is. Cells were treated with (A) navtemadlin or (B) idasanutlin at the indicated doses for 3 days, and then cell viability was measured by assay with 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS). Cells treated with dimethyl sulfoxide were the control (Cntr), and their viability was set as 1. Each experiment was performed in quadruplicate and repeated at least twice. Values are means for quadruplicate assays; error bars are standard deviations (SDs). (C) Western blot analysis for proteins at the basal level and cells harvested 24 hours after treatment. (D) Heatmap of treatment-induced protein changes. Cells derived from XABCLs and human lymphoma cell lines were treated with solvent or 1 µM navtemadlin for 3, 8, or 24 hours, and cell lysates were subjected to RPPA analysis. The levels of proteins that had significant difference after treatment with solvent control and navtemadlin (adjusted P < .05) are presented in the heatmap scaled from low to high as blue-white-red. (E) BCL6 levels in RNA-seq data of 15 XABCLs and 480 patients with DCLBL from the NCICCR in The Cancer Genome Atlas database. Levels of BCL6 in each sample were normalized with total numbers of reads mapped to the human genome and then normalized with housekeeping gene VPS29 as indicated. The values represent the median (line inside box) and the third and first quartile (box) ±1.5 × the interquartile range from the top and bottom of the box (error bar), whereas the dots represent individual values.